Approval of 'race-based' drug is stimulating efforts to detect and predict true subgroups for drug response
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Branca, M. BiDil raises questions about race as a marker. Nat Rev Drug Discov 4, 615–616 (2005). https://doi.org/10.1038/nrd1812
Issue Date:
DOI: https://doi.org/10.1038/nrd1812
This article is cited by
-
Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions
Oncogene (2006)
-
Response to BiDil's impact
Nature Biotechnology (2005)